Simvastatin impairs murine melanoma growth

Area of Science:

• Pharmacology and Oncology
• Cancer Research

Background:

• Statins, including simvastatin, exhibit pleiotropic effects such as cell cycle arrest, apoptosis induction, and inhibition of angiogenesis.
• These properties suggest a potential role for statins in cancer therapy, particularly in models involving tumor growth and metastasis.

Purpose of the Study:

• To investigate the anti-tumoral activity of simvastatin in a B16F10 melanoma mouse model.
• To evaluate the efficacy of simvastatin as a potential antiproliferative agent against melanoma.

Main Methods:

• In vitro: Melanoma cells were treated with varying concentrations of simvastatin to assess cytotoxicity and cell cycle effects.
• In vivo: B16F10 melanoma cells were implanted in C57Bl6/J mice, followed by oral administration of simvastatin (5 mg/kg/day).
• Tumor size, hematological, and biochemical parameters were monitored throughout the study.

Main Results:

• Simvastatin exhibited dose-dependent cytotoxicity, with significant cell death observed at concentrations of 0.8 μM, 1.2 μM, and 1.6 μM.
• In vitro, simvastatin at 0.8 μM induced G0/G1 cell cycle arrest and increased hypodiploidy.
• In vivo, simvastatin treatment resulted in a 68% inhibition of tumor expansion compared to the control group after ten days.

Conclusions:

• Simvastatin displays significant antiproliferative and cytotoxic effects against melanoma cells in vitro and in vivo.
• The findings suggest that simvastatin holds potential as an antiproliferative drug for melanoma treatment, warranting further investigation.